Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Diagnocure CUR -- Ignore unavailable to you. Want to Upgrade?

To: Mr. L. Neufeldt who wrote (124)	8/2/2001 9:30:45 AM
From: john.d	Read Replies (1) \| Respond to of 132

I wonder how this new test will impact Diagnocure? John ca.us.biz.yahoo.com Vysis says FDA approves bladder cancer test NEW YORK, Aug 2 (Reuters) - The U.S. Food and Drug Administration has approved Vysis Inc.'s (NasdaqNM:VYSI - news) gene-based test for the recurrence of bladder cancer, the company said on Thursday. Vysis, which makes medical devices and products that test for genetic diseases, said the bladder-cancer test, called UroVysion, is based on the detection of genetic changes in bladder cells using the company's ``fluorescence DNA probe'' technology. It is the drug industry's first genomic DNA-probe test for monitoring recurrence of bladder cancer to be cleared by the FDA, the company said. Vysis said recent surveys estimated there would be about 53,000 new cases of bladder cancer diagnosed in 2001 in the United States and 83,000 in the European Union. The company estimated there are well over one million patients living with the disease in the United States and Europe. Vysis shares closed at $24 on Wednesday, off a 52-week high of $29.50 and above a low of $5.22